can tirzepatide cause eye problems GLP-1 Medications and Your Vision: What You Should Know Popular weight-loss drugs could increase

In the TRIUMPH-1 Phase 3 trial, participants experienced an average weight loss of 28.3% at 80 weeks

The diagnostic spectrum of hypercalcemia

The role of dynamin-related protein 1, a mediator of mitochondrial fission, in apoptosis

Zepbound is expected to be available in the U.S

A $79.99 blend becomes roughly $20 per payment

At SOF Week 2026, Regina Gina Sims, Director of the Department of Wars (DoW) Small Business Innovation Research and Small Business Technology Transfer (SBIR/STTR) Program Office under the Undersecretary of Defense for Research and Engineering, briefed on the programs reauthorization, structural overhaul and new funding mechanisms